Form D · Biotechnology

Pacegenix, Inc.

Cambridge, MA · CIK 0002117706

Offering snapshot reported Mar 26, 2026 · SEC filing

Reported sold
$22.5M
Offering amount: $22.5M
Investors reported
15
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 11, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 26, 2026Initial$22,533,267No comparison15SEC filing

Offering details

Securities
Equity, Debt, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$578K (estimated)
Finders' fees
$0
Form D file number
021-577711
SAFE Convertible Notes
Includes equity issued as sales compensation per engagement letter dated 2/10/25: 300,000 shares issued to LifeSci at or around 2/10/25 at $0.0001 per share, fair market value of $30, consistent with Rule 501(c) and Form D Item 13 valuation methodology.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
LifeSci Capital, LLC168404LifeSci Capital, LLC · CRD 168404

Source: Form D, filed Mar 26, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Fredric Neville Eshelman Director
Frank Grazzini, Ii Executive
Raymond Tabibiazar Director
Jay Glenn Wohlgemuth Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
245 1 St St, 18 Th Floor
Cambridge, MA, 02142